Factor IX Complex injection
What is this medicine?
FACTOR IX COMPLEX (FAK ter nyne KUM pleks) is used in patients with hemophilia B to help control bleeding.
How should I use this medicine?
This medicine is for injection into a vein. It is given by a health care professional in a hospital or clinic setting.
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
changes in vision
confusion, trouble speaking or understanding
cough or other signs of infection
fever or chills
shortness of breath, chest pain, swelling in a leg
sudden numbness or weakness of the face, arm or leg
trouble walking, dizziness, loss of balance or coordination
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
What may interact with this medicine?
This medicine may interact with the following medications:
What if I miss a dose?
Keep appointments for follow-up doses as directed. It is important not to miss your dose. Call your doctor or health care professional if you are unable to keep an appointment.
Where should I keep my medicine?
This drug is given in a hospital or clinic and will not be stored at home.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
history of blood clots
history of heparin-induced thrombocytopenia
an unusual or allergic reaction to factor IX complex, heparin, other medicines, foods, dyes, or preservatives
pregnant or trying to get pregnant
What should I watch for while using this medicine?
If you are a hemophilia patient, carry an identification card with you at all times. The card should have your name, the name and dose of your medication(s), the name and phone number of your doctor or health care professional, and a contact person in case of an emergency.
September 30, 2017